MYRELEZ L.P. 120 mg, extended-release solution for injection in a pre-filled syringe syringe, 0.5 ml
Active ingredients: Lanreotide acetate, Lanreotide
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release solution for injectionsyringe, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MYRELEZ L.P. 120 mg, solution injectable à libération prolongée en seringue préremplie
- Pharmaceutical form
- solution injectable à libération prolongée
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue préremplie polypropylène de 0,5 ml avec aiguille(s) avec système de sécurité automatique
- Marketing authorisation holder
- AMDIPHARM
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 25 Apr 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61670321CIP73022836CIP133400930228364Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LANRÉOTIDE BASEsolution | — | FT |
| ACÉTATE DE LANRÉOTIDEsolution | 120 mg · une seringue préremplie | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.